SCHEMBL6857665

SCHEMBL6857665

CCN(C(=O)OC(C)(C)C)n1c(C)c(C(=O)OC)c2cnccc2c1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.34
MAPK8 P45983 1/20 0.33
MAPK9 P45984 1/20 0.33
MAPK10 P53779 1/20 0.33
KDM4E B2RXH2 6/20 0.33
MAPK1 P28482 3/20 0.33
NPSR1 Q6W5P4 1/20 0.33
KDM5A P29375 1/20 0.33
KDM5B Q9UGL1 1/20 0.33
PARP1 P09874 1/20 0.33
CSNK2A1 P68400 1/20 0.33
HTT P42858 3/20 0.32
DGAT2 Q96PD7 1/20 0.32
ALDH1A1 P00352 4/20 0.32
HPGD P15428 4/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
MAPT P10636 2/20 0.32
KAT2B Q92831 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6857387 0.92 KDM4E (0.34) NAMPTMAPK8MAPK9MAPK10KDM4E
SCHEMBL2453240 0.90 KDM5A (0.34) NAMPTKDM4EKDM5AKDM5BHTT
SCHEMBL2369631 0.84 KDM5A (0.40) KDM4EKDM5AKDM5BHTTALDH1A1
SCHEMBL2381471 0.82 NAMPT (0.33) NAMPTKDM5AKDM5B
SCHEMBL2370205 0.82 TDP1 (0.34) NAMPTKDM4ENPSR1KDM5AKDM5B
SCHEMBL2453835 0.81 KDM4E (0.38) MAPK8MAPK9MAPK10KDM4EMAPK1
SCHEMBL2370137 0.73 KDM4E (0.39) KDM4EHTTALDH1A1SMN1; SMN2MEN1
SCHEMBL2383432 0.72 CYP2C9 (0.42)
SCHEMBL2383435 0.72 CYP2C9 (0.42)
SCHEMBL2369636 0.67 KDM5A (0.39) KDM4ENPSR1KDM5AKDM5BHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130190499-A1 Azaisoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2013-07-25 US disclosed
US-20130190499-A1 Azaisoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2013-07-25 US disclosed
US-20110224247-A1 AZAISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2011-09-15 US disclosed
US-20110224247-A1 AZAISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2011-09-15 US disclosed
WO-2011110183-A1 AZAISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2011-09-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224247-A1 AZAISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNQ3, KCNK3, KCND3 NAMPT 1596/4885MAPK8 2381/4885MAPK9 3709/4885
US-20130190499-A1 Azaisoquinolinone derivatives as NK3 antagonists KCNQ3, KCNK3, KCND3 NAMPT 1596/4885MAPK8 2381/4885MAPK9 3709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.